Journal of Shanghai Jiao Tong University (Medical Science) >

2020 , Vol. 40 >Issue 5: 693 - 697

DOI: https://doi.org/10.3969/j.issn.1674-8115.2020.05.023

Review

Research progress of the mechanism of rituximab in the treatment of focal segmental glomerulosclerosis

  • 季垠宏，任 红
Expand
  • Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Online published: 2020-05-28

Fold

Abstract

Rituximab (RTX), as a monoclonal antibody of CD20 acting on B cell epitopes, has been applied to the field of kidney since 2005, and has become a research hotspot in the clinical treatment of glomerulonephritis. At present, in addition to its clinical safety and efficacy, some researchers are still committed to explore the mechanism of RTX in the treatment of renal diseases, trying to find out whether there is a specific target in renal tissue. In this paper, the mechanism of RTX in the treatment of focal segmental glomerulosclerosis is reviewed.

Key words： rituximab (RTX); focal segmental glomerulosclerosis (FSGS); sphingomyelin phosphodiesterase acid-like 3b (SMPDL-3b)

Cite this article

季垠宏，任 红 . Research progress of the mechanism of rituximab in the treatment of focal segmental glomerulosclerosis[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2020 , 40(5) : 693 -697 . DOI: 10.3969/j.issn.1674-8115.2020.05.023

Options
Outlines

/

〈 〉